Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma previously treated with at least one line of systemic therapy

Epcoritamab is in clinical development for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after one or more lines of therapy. DLBCL is a cancer of B cells, a type of immune cell, and the most common type of fast-growing non-Hodgkin’s lymphoma - a disease in which cancer cells form in the lymph system, which forms part of the immune system. Relapsed or refractory DLBCL refers to the disease reappearing after treatment or when the lymphoma does not respond to treatment. In DLBCL, the body makes abnormal B cells which build up in lymph nodes or other body organs. The affected cells start to divide before they are fully mature and lose their infection-fighting properties, which makes the body more vulnerable to infection. A high proportion of cases of DLBCL relapse or are refractory to treatment with currently available therapies.